Why does skin itch?

Think about what your skin is for. Not what it looks like — what it does. It is the wall between you and everything else: dust, soap, pollen, bacteria, cold air. A wall has two jobs. Keep the outside out, and keep the inside in.

Now picture the wall built out of bricks and mortar. The bricks are skin cells. The mortar is a mix of fats and proteins packed into the gaps. If the mortar is thin, two things happen at once. Water escapes from inside, so the skin dries out. And things from outside get in, so the immune system meets substances it would normally never see.

That is eczema. Not one problem, two — and they feed each other.

The gene that gave it away

For a long time eczema was described mostly as an immune problem: the immune system overreacting to something harmless. That is real, but it left a question. Why do some people's immune systems meet these things in the first place?

In 2006, a research group studied families with very dry, scaly skin and found something specific. People with broken copies of a gene called filaggrin were far more likely to have eczema.

Filaggrin's job is to help make the mortar. Break the gene, and you build a wall with gaps in it.

This mattered because it changed the order of events. The barrier can fail first, and the immune reaction can follow. That is a different disease than the one people thought they were treating, and it suggests a different place to intervene — the wall, not only the alarm.

Why nobody has fixed it

Here is the part worth sitting with. Filaggrin is one of the best-evidenced findings in all of eczema research, and there is still no approved drug and no clinical candidate aimed at it for eczema.

That wording matters. Some of the other genes on that list do have drugs — just approved for different diseases. "Nothing for eczema" and "nothing anywhere" are different claims, and mixing them up is one of the easiest mistakes to make when reading a database.

Not because anybody forgot. Filaggrin is a large structural protein, and most medicines work by blocking something — sticking to a target and switching it off. Blocking is a solvable problem. Replacing a missing building material is a much harder one, and nobody has a good way to do it yet.

So the drugs that exist mostly work downstream, calming the immune reaction after the barrier has already failed. They help. They are genuinely good medicines. But they are treating the second half of the story, because the first half is harder.

That gap — strong evidence, no drug — is the thing this foundation looks for. It turns up more often than you would expect.

Try this

Open Open Targets, a free database that collects the evidence linking genes to diseases. No account, no cost.

1. Go to https://platform.opentargets.org and search for atopic eczema.
2. Open the list of associated targets. Each gene gets a score from 0 to 1 for how much evidence supports it.
3. Find FLG — that is filaggrin. Look at how high it scores.
4. Now click the Known Drugs section for it, and see what comes back.

You have just checked a real scientific claim against the real data, in about ten minutes, for free. That is most of what research actually is.

One question to take away

If the best evidence points at a target nobody has drugged, is that a dead end — or is it the most interesting place to look?

---

Source: Palmer et al., "Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis," Nature Genetics, 2006. PMID 16550169.